Trinity Capital Funds $20M for Emboliner Trial Completion and Commercial Prep
Trinity Capital committed $20 million in growth capital to Emboline to advance its Emboliner embolic protection catheter, which recently completed patient enrollment in the PROTECT H2H IDE clinical trial. The financing will support manufacturing scale-up, team expansion and regulatory milestones ahead of Emboliner’s planned commercial launch.
1. $20 Million Growth Capital Commitment
Trinity Capital has committed $20 million in growth financing to Emboline, supporting the development of its Emboliner embolic protection catheter designed to reduce strokes during heart procedures.
2. Emboliner System Clinical Progress
Emboline has completed patient enrollment in the PROTECT H2H IDE trial, advancing towards regulatory approval by gathering critical safety and efficacy data on its flexible mesh embolic protection device.
3. Financing Allocation and Commercial Plans
The funds will enable Emboline to scale manufacturing capacity, expand its workforce, and meet clinical and regulatory milestones required for an anticipated Emboliner system commercial launch.
4. Strategic Impact on Trinity Capital
This investment underscores Trinity Capital’s focus on life sciences lending, adding to its $5.5 billion deployment track record and diversifying its portfolio across growth-oriented MedTech ventures.